Get the Stockscreener App
1.68
2.89%
-0.05
In 8 Bio Inc stock is traded at $1.68, with a volume of 85,790.
It is down -2.89% in the last 24 hours and down -1.18% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.73
Open:
$1.76
24h Volume:
85,790
Relative Volume:
1.28
Market Cap:
$7.79M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.24
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-5.08%
1M Performance:
-1.18%
6M Performance:
-29.41%
1Y Performance:
-80.73%
1-Day Range:
$1.67
$1.87
1-Week Range:
$1.67
$1.87
52-Week Range:
$1.5301
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.68 | 8.02M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
The 4 billion won investment quietly implemented by Yuhan four years ago returned to a "large jackpo.. - 매일경제
Pres Kalowski Sells 9,072 ($31.4K) Of Q32 Bio Inc [QTTB] - TradingView
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Upstream Bio (NASDAQ:UPB) Shares Down 8%Here's What Happened - MarketBeat
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Risk Off: Will Passage Bio Inc. stock sustain high P E ratiosQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Officer Liu Files To Sell 10,000 Of Nuvation Bio Inc [NUVB] - TradingView
KALA BIO Form 3 shows CEO and director hold no KALA stock - Stock Titan
Can Korro Bio Inc. stock surprise with earnings upsideWeekly Profit Summary & Growth Focused Stock Pick Reports - BỘ NỘI VỤ
Nuvation Bio Inc Discontinues NUV-1511 Development - TradingView
Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS]-Amended - TradingView
KALA BIO, Inc. Announces Executive and Board Changes - TradingView
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Chmn Hoffman Buys 39,200 ($159.9K) Of Annovis Bio Inc [ANVS] - TradingView
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Officer Hattersley Sells 369,051 ($2.7M) Of Nuvation Bio Inc [NUVB] - TradingView
Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS] - TradingView
Officer Hanley Sells 200,000 ($1.4M) Of Nuvation Bio Inc [NUVB] - TradingView
Officer Hattersley Files To Sell 369,051 Of Nuvation Bio Inc [NUVB] - TradingView
Officer Liu Files To Sell 20,000 Of Nuvation Bio Inc [NUVB] - TradingView
Nuvation Bio Surges On Ibtrozi Momentum And B. Riley Buy Rating (NYSE:NUVB) - Seeking Alpha
Officer Liu Sells 30,000 ($148K) Of Nuvation Bio Inc [NUVB] - TradingView
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
[Form 4] Inmune Bio, Inc. Insider Trading Activity - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - Yahoo Finance
Nuvation Bio Inc Publishes Positive Phase 2 Study Results for Safusidenib - TradingView
Adicet Bio special meeting to vote on flexible reverse stock split - Stock Titan
[8-K] TELA Bio, Inc. Reports Material Event | TELA SEC FilingForm 8-K - Stock Titan
Korro Bio, Inc. (KRRO): RBC Capital Initiates “Sector Perform” Rating with Upside Potential - Stocks Telegraph
[8-K] Instil Bio, Inc. Reports Material Event | TIL SEC FilingForm 8-K - Stock Titan
[8-K] Annovis Bio, Inc. Reports Material Event | ANVS SEC FilingForm 8-K - Stock Titan
[S-8] PALISADE BIO, INC. Employee Benefit Plan Registration | PALI SEC FilingForm S-8 - Stock Titan
[Form 4] Annovis Bio, Inc. Insider Trading Activity - Stock Titan
Inmune Bio, Inc. Announces Key Developments in Clinical Programs - TradingView
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
[8-K] Cabaletta Bio, Inc. Reports Material Event | CABA SEC FilingForm 8-K - Stock Titan
Belite Bio Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
KALA BIO Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire Inc.
[8-K] Climb Bio, Inc. Reports Material Event | CLYM SEC FilingForm 8-K - Stock Titan
Climb Bio, Inc. SEC 10-Q Report - TradingView
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):